logo
  

Enerlabs Acquires Zalco Laboratories - Quick Facts

Enerlabs Inc. (EGSRD.PK) on Monday said it has purchased its first strategic laboratory, Zalco Laboratories, Inc., within the new organization as of close of business Friday, February 03.

Enerlabs noted that the deal is made with a one year note bearing 4% interest, and the note can be converted to common stock at a value of $1.00 per share. This allows the selling lab owners to participate in the growth of Enerlabs and gives them liquidity while they retain their employment, if they so choose.

California -based Zalco is a full service analytical laboratory, serving the industries of petrochemical, petroleum products, refinery, manufacturing, wine manufacturing and solution based special projects. It employees 25 people and its client list includes: BP, Chevron, Edwards AFB, surrounding municipalities, oil & gas producers and several refineries.

The company noted that Zalco has just opened a satellite location in Ventura, California as of the first of November last year primarily targeting the petroleum refinery business in the Ventura market.

It is expected that ZALCO will finish the year with sales estimated in the $2.5 to $3 million range, proving the company's market potential.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT